Tobira's CCR5 antagonist passes Phase IIa HIV trial
19 February 2010
Asher Mullard
Please Login to read the full article.
19 February 2010
Asher Mullard
Asher.mullard@informa.com
Tobira's CCR5 antagonist TBR-652 met its primary endpoint in a Phase IIa trial in HIV, show data presented by the company yesterday at the Conference on Retroviruses and Opportunistic Infections (CROI). In a separate presentation at CROI, Merck presented detailed data from two recently failed Phase...
Please Login to read the full article.
RELATED CONTENT
EVENTS
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
26 March 2012
Copenhagen, Denmark
JOB OF THE WEEK
Promote your vacancy here
